Scancell Holdings PLC. (SCNLF)

[Gift_Horse]

GG Gums,

Actually the target price (issued by the award winning analyst, Navid Malik, of Cenkos Securities) is 127.89 pence to be precise (£1.27). Although Yahoo has it as a 1 year target (as they do with all submitted targets) the target itself is a momentum target and is an indication of where the stock might climb given expected news flow.

In Autumn (most likely September) Scancell is to give details of its new vaccine technology called Moditope™. Vaccines against cancer and viruses stimulate Killer T Cells to attack and destroy these diseases. Scancell's Moditope™ for the first time induces a rare type of Killer T Cell known as a CD4 Killer T Cell. They are more long lasting in their killing effect than the existing type of cancer and virus killing cells available to scientists at the moment which are known as CD8 Killer T Cells. Normally CD4 T Cells don't kill directly but they do help the CD8 Killers to increase in number. Scancell has found a way of causing these CD4 Helper Cells (as they are commonly known) to switch their roles from simple helpers to full blown killers. This is the first time that anyone has successfully done this.

Scancell now plans to showcase this technology in a vaccine of its own and to license this new discovery to other companies to make their vaccines work more powerfully. For instance, patients who get infected with HIV and don't develop AIDs are believed to be protected by their body's rare ability to switch its own CD4 Helper Cells into these tireless Killers which then go on to eradicate or prevent the HIV infection. So Scancell expects its technology to be used not only to make cancer vaccines more potent but also by vaccine manufacturers to fight HIV and other infectious diseases.

The discovery of Moditope™ was first announced last August (2012) but Scancell has been given 1 year to finalize its patent before filing. That period ends next month and the details of the discovery are expected to be published for the first time in September. This is likely to be accompanied by a great deal of publicity on both sides of the pond. The share price could easily hit a dollar or more at that time.

Moditope™